Vicki Kelemen | Vice President, Clinical Development
Vicki Kelemen joined Trovagene as Sr. Director, Marketing Communications in 2015 and was promoted to VP, Corporate Communications in 2017 and in 2018 was promoted to VP, Investor Relations and clinical development.
Prior to joining Trovagene, Ms. Kelemen was Sr. Vice President at a global healthcare communications agency, where she specialized in the market development and commercialization of therapeutics for serious and rare diseases, as well as the development of patient advocacy programs. Previously, Ms. Kelemen held progressive marketing and communications management positions and lead the launch of several novel products with pharmabiotech companies focused in therapeutics, diagnostics and medical devices, including Amylin, Maxim, Agouron (Pfizer) and Dura Pharmaceuticals. Ms. Kelemen began her career in healthcare with Bayer Pharmaceuticals, where she held positions is sales, sales training, and marketing.
Ms. Kelemen has a BS degree from the University of California at Davis.